Penn Medicine Provider
Gastroenterology
Meenakshi Bewtra, MD, MPH, PhD
4.9
(67)
Accepting new patients
Sees patients age 18 and up
Penn Gastroenterology Perelman

About me

  • Co-Section Head and Research & Education Director, Penn Inflammatory Bowel Diseases Program
  • Associate Professor of Medicine (Gastroenterology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: University of Pennsylvania School of Medicine
  • Residency: Hospital of the University of Pennsylvania
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
4.9

67 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
she is thorough and has great bedside manner
April 2025
5.0
5.0
she was attentive. answered all my questions & concerns. we discussed the vaccines i needed to get updated. very thorough appointment.
February 2025
5.0
5.0
she was prepared and ready for our visit.
February 2025
5.0
5.0
dr. bewtra is extremely knowledgeable. she listened to my concerns and i left her office feeling relieved to have a new treatment plan. dr. bewtra is excellent doctor and i highly recommend her!

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Bewtra is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Bewtra, Meenakshi; Schreiber, Stefan; Buisson, Anthony; Hur, Peter; Panattoni, Laura; Hauber, Brett; Gahlon, Grace; Coulter, Josh; Smith, Christina; Guo, Xiang; Land, Natalie; Wosik, Karolina; Cappelleri, Joseph; Maravic, Melissa Culhane; Walsh, Alissa Comparing the benefit-risk tradeoffs advanced therapy naïve vs experienced patients are willing to accept when selecting advanced therapy for moderate-to-severe ulcerative colitis: A discrete choice experiment in the United States and Europe , Digestive Disease Week, San Diego CA: 2025


Schreiber, Stefan; Buisson, Anthony; Bewtra, Meenakshi; Hur, Peter; Panattoni, Laura; Hauber, Brett; Land, Natalie; Coulter, Josh; Gahlon, Grace; Guo, Xiang; Smith, Christina C.; Cappelleri, Joseph C.; Wosik, Karolina; Maravic, Melissa Culhane; Walsh, Alissa Quantifying the benefit-risk trade-offs adult patients and providers are willing to make when considering advanced therapies for moderate to severe Ulcerative Colitis: A discrete choice experiment , European Crohn’s and Colitis Organisation 2025; Berlin Germany: 2025


Sehgal P, Lewis JD, Pickett-Blakely O, Nandi N, Bewtra M, Lichtenstein GR. Safety and Clinical Effectiveness of GLP1 Receptor Agonists in Inflammatory Bowel Disease Patients , Clin Gastroenterol Hepatol: 2025


Kastl AJ, Brenner EJ, Weaver KN, Zhang X, Strople JA, Adler J, Dubinsky MC, Bousvaros A, Watkins R, Dai X, Chen W, Cross RK, Higgins PDR, Ungaro RC, Bewtra M, Bellaguarda EA, Farraye FA, Chun KY, Zikry M, Bastidas M, Firestine AM, Craig RG, Boccieri ME, Long MD, Kappelman MD. Durable Immune Response and Long-term Efficacy of COVID-19 Vaccination in Children With Inflammatory Bowel Disease , Inflamm Bowel Dis: 2024


Motwani KK, Alizadeh M, Abutaleb A, Grossman J, Wellington J, Cross RK; SPARC-IBD investigators. Correlation Between Serum and Fecal Biomarkers and Patient-Reported Outcomes in Patients with Crohn's Disease and Ulcerative Colitis , Dig Dis Sci: 2024


Motwani KK, Alizadeh M, Abutaleb A, Grossman J, Wellington J, Cross RK; SPARC-IBD investigators. Correction to: Correlation Between Plasma and Fecal Biomarkers and Patient‑Reported Outcomes in Patients with Crohn's Disease and Ulcerative Colitis , Dig Dis Sci: 2024


Karakasheva TA; Martinez CM; Zhou Y; Rhoades JH; Soto GE; Hix OT; Nettleford SK; Roach DM; Laguerta AM; Thadi A; Aleynick D; Pickering OH; Borodyanskaya Y; Fulton M; Uzun Y; Li N; Bewtra M; Kelsen JR; Tan K; Minn AJ; Lengner CJ; Hamilton KE; Crohn's Disease Epithelial Cells Exhibit Sustained Inflammatory Progenitor Cell States , Digestive Disease Week, Washington DC: 2024


Lewis JD, Daniel SG, Li H, Hao F, Patterson AD, Hecht A, Brensinger CM, Wu GD, Bittinger K; DINE-CD; SPARC IBD Investigators. Surgery for Crohn's Disease Is Associated with a Dysbiotic Microbiome and Metabolome: Results from Two Prospective Cohorts , Cell Mol Gastroenterol Hepatol: 2024


Sehgal P; Khanna T; Profka K; Pickett-Blakely O; Nandi N; Rashid F; Bewtra M; Lewis JD; Lichtenstein, GR; Aberra F. Safety and Clinical Effectiveness of GLP1 Agonists in Inflammatory Bowel Disease Patients , Digestive Disease Week, Washington DC: 2024


Sehgal P; Khanna T; Profka K; Pickett-Blakely O; Nandi N; Rashid F; Bewtra M; Lewis JD; Lichtenstein, GR; Aberra F. Impact of GLP1 agonists on inflammatory biomarkers in patients with IBD , Digestive Disease Week, Washington DC: 2024


View all publications